Sepsis: Broad-Spectrum PCR-Test Receives CE-IVD Approval
News Sep 30, 2008
Today’s conventional microbiological methods usually deliver results, on an average, only after 48 hours. SepsiTest™ received CE-IVD-marking according to European in-vitro diagnostic law and is now available for routine sepsis diagnostics.
Sepsis (coll. blood poisoning) is a systemic inflammation of the whole body ultimately leading to multiple organ dysfunctions. Even though the latest intensive care technology can maintain organ function in critical phases for
some time, sepsis is an extremely severe prognosis. Despite greatest efforts, septicemic patients today still have a mortality rate of 30-50%. Several researchers have estimated that, in the U.S. alone, more than 580
patients die from sepsis every day. The survival rate greatly depends on an early therapy including targeted antibiotic treatment.
Today, sepsis-causing pathogens are usually identified by a traditional microbiological method: the so-called blood culture. Blood culture tests normally deliver results after 2 to 5 days and, in some cases, the analysis
takes even longer. Moreover, blood cultures are limited when detecting fastidious organisms or when antibiotic therapies have already been administered. Therefore, molecular biologists have been working for quite some
time on rapid sepsis screening technologies. In contrast to other molecular tests, the broad-spectrum SepsiTest™ detects all relevant pathogens and, thus, for the first time enables very targeted antibiotic therapies. Latest research from SepNet, the European sepsis network, showed dramatically increased survival
rates for sepsis patients receiving early and targeted antibiotic treatments.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.